Cost-effectiveness analysis of pregabalin for the treatment of neuropathic pain in Colombia

Abstract

Kong SLE patients compared to standard care. METHODS: A lifetime microsimulation model was adapted with epidemiological and cost data from Hong Kong. The model compares the use of belimumab against standard care and incorporates the BLISS-52 and BLISS-76 trial data for the short term outcomes within one year, while long-term outcomes were based on a natural history model developed using the Johns Hopkins Lupus registry. The natural history model describes the relationship between disease activity and other covariates on the risk of dying and developing organ damage. Data available from the SLE population in Hong Kong was used as input in the modified model. The analysis was performed from a Hong Kong health-care perspective. In the base case, cost and effectiveness were discounted to the year of analysis at 5% p.a. RESULTS: The base case analysis showed that compared to standard care, treatment with belimumab increased life expectancy by 0.80 (2.77 undiscounted) and QALY by 0.60 (1.68 undiscounted) years respectively.

Economic burden of herpes zoster in Latin America: A systematic review and meta-analysis

“…Table 1 provides an overview of cost per patient data. Studies reported different perspectives when estimating costs such as social perspective (n = 3), 49 , 59 , 60 third-party payer perspective (n = 1) 64 and the public perspective (n = 1). 65 Out-of-pocket expenses were reported in two studies.…”

“…Most economic studies were of adequate quality. However, of the eight studies with economic study designs, 49–52 – 58–65 only one study 60 used the discount rate, while none of the studies adjusted their cost estimates based on inflation rates. Four studies did not report any comparator, and three studies did not report any estimation of direct or indirect costs.…”